@article{26954bcca3b74c70b74bf37eba2bb959,
title = "The importance of an early onset of migraine preventive disease control: A roundtable discussion",
abstract = "Background: Newly approved migraine preventive therapies have allowed for rapid control of migraine activity, offering potential to minimize the burden of migraine. This report summarizes a roundtable discussion convened to analyze evidence for early onset of prevention, ascertain its clinical relevance, and provide guidance for healthcare professionals in crafting goals and treatment expectations for patients with migraine initiating preventive therapy. Methods: A virtual roundtable meeting of migraine clinicians, researchers, and patient advocates convened in October 2020. Participants reviewed and discussed data summarizing patient and healthcare professional perceptions of migraine prevention and evidence from the peer-reviewed and gray literature to develop corresponding recommendations. Summary: Evidence from clinical studies of anti-calcitonin gene-related peptide monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and the chemodenervation agent onabotulinumtoxinA indicate that patients may experience reduction of migraine activity within 7 days of drug administration and early attainment of disease control is associated with improvements in clinically important outcomes. The roundtable of experts proposes that early onset be defined as demonstration of preventive benefits within 1 week of treatment initiation. We recommend focusing discussion with patients around “disease control” and potential benefits of early onset of prevention, so patients can set realistic preventive therapy goals and expectations.",
keywords = "CGRP, early onset, migraine, prevention",
author = "Christopher Gottschalk and Anirban Basu and Andrew Blumenfeld and Bradley Torphy and Marmura, {Michael J.} and Pavlovic, {Jelena M.} and Dumas, {Paula K.} and Nim Lalvani and Buse, {Dawn C.}",
note = "Funding Information: The authors thank Philip Sjostedt, BPharm, MPH, of The Medicine Group, LLC (New Hope, PA, United States) for providing medical writing support, which was funded by Lundbeck LLC (Deerfield, IL, USA) in accordance with Good Publication Practice guidelines. The authors have authorized the submission of this manuscript by The Medicine Group on their behalf and have approved any statements and declarations. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was sponsored and funded by H. Lundbeck A/S and Lundbeck Seattle BioPharmaceuticals, Inc., who also provided funding for the development of materials and who hosted the roundtable discussion. All authors participated in the roundtable; prepared, reviewed, and approved the manuscript; and made the decision to submit the manuscript for publication. Editorial support for the development of this manuscript was funded by Lundbeck A/S. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was sponsored and funded by H. Lundbeck A/S and Lundbeck Seattle BioPharmaceuticals, Inc., who also provided funding for the development of materials and who hosted the roundtable discussion. All authors participated in the roundtable; prepared, reviewed, and approved the manuscript; and made the decision to submit the manuscript for publication. Editorial support for the development of this manuscript was funded by Lundbeck A/S. Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: CG has been a paid consultant for Alder/Lundbeck, Biohaven, Amgen/Novartis, Theranica, Axsome, Upsher Smith, Spherix Global Insights, and Vorso. Past member of speaker bureaus: Amgen/Novartis, Allergan/Abbvie, Biohaven, Lilly, Theranica, and Upsher Smith. Editorial duties: Associate Editor, Headache. Board member: Headache Cooperative of New England (HCNE). A Basu has received consulting fees through his work with Salutis Consulting LLC outside of this work. He was a paid consultant for Lundbeck to attend the roundtable. A Blumenfeld serves as a consultant and/or a promotional speaker for Alder, Allergan, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Novartis, Promius, Supernus, Teva, and Theranica. BT has received compensation for consulting from Amgen, Novartis, Biohaven, Lilly, Lundbeck, Teva, and Theranica. He has participated in speaker bureaus with Allergan/Abbvie, Amgen, Biohaven, Lilly, Lundbeck, and Teva, and he has received financial compensation for serving as principal investigator with Amgen and Theranica. MJM has received compensation for consultation from Lundbeck and Theranica. He has participated in speaker bureaus for Lilly and Amgen/Novartis. He has received salary support for serving as principal investigator from Teva, GammaCore, and Allergan/AbbVie. He has received payments for authorship or royalties from Demos Medical, Cambridge University Press, and MedLink. JMP has received grant support from the National Institutes of Health and compensation for consulting from Alder/Lundbeck, Allergan/Abbvie, Amgen/Novartis, and Biohaven. PKD has received grant support from Amgen/Novartis, Allergan/AbbVie, and Lilly. She serves as Editor in Chief of Migraine Again, Editor at Large of Everyday Health, and Co-Producer/Co-Owner of Migraine World Summit, which is supported by Lundbeck, Impel, Lilly, Allergan/AbbVie, Axon Optics, and Teva. NL declares that there is no conflict of interest. She has no compensation to report; all funding or sponsorships are directed to the American Migraine Foundation. DCB has received grant support from the Food and Drug Administration and the National Headache Foundation and grant support and honoraria from Allergan, Amgen, Lilly, Lundbeck, and Teva. She serves on the editorial board of Current Pain and Headache Reports. Publisher Copyright: {\textcopyright} The Author(s) 2022.",
year = "2022",
doi = "10.1177/25158163221134593",
language = "English (US)",
volume = "5",
journal = "Cephalalgia Reports",
issn = "2515-8163",
publisher = "SAGE Publications Ltd",
}